is an effective and safe treatment option for children with severe refractory headache, new research suggests.
Rosenthal reported the findings on April 15 at the American Academy of Neurology 2024 annual meeting."IV ketamine has shown benefit in nonheadache chronic pain syndromes and refractory mood disorders. Patients with refractory status migraines are often left with ongoing pain and dysfunction after failing typical interventions," Rosenthal said.
Rosenthal and colleagues took a look back at patients admitted to Children's Hospital Colorado between 2019 and 2022 for treatment of severe refractory headache who were treated with continuous IV ketamine. There were no serious adverse events and no cardiac side effects; 7% stopped treatment due to side effects. The most common side effects were dizziness , nausea , blurred vision , hallucinations , cognitive fog , vomiting and dysphoria , worsening headache , and parasthesia and cramping .At baseline, pain scores were 8 and progressively fell during treatment.
Pain Management Pain Chronic Pain Refractory Migraine Migraine Headache Children Child Childhood Pediatrics Kids Chronic Pain Syndrome Patient Safety Adverse Effects Side Effects Hospitals Colorado Hallucination Intravenous IV - Intravenous Intravenous Route
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Abecma Approved for Earlier Lines in Relapsed/Refractory Multiple MyelomaThe drug manufacturers report a complete response rate of 39% with idecabtagene vicleucel (Abecma) vs 5% with standard regimens.
Source: Medscape - 🏆 386. / 55 Read more »
FDA Approves ide-cel for Adults with Relapsed or Refractory Multiple MyelomaThe FDA has approved ide-cel, a chimeric antigen receptor (CAR) T-cell therapy, for adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy. The approval expands the therapy's indications to earlier lines of treatment after exposure to other main therapy classes.
Source: Medscape - 🏆 386. / 55 Read more »
Coronary Sinus Reducer Shows Promise in Treating Refractory AnginaA coronary sinus reducer device has been found to be a viable therapeutic option for patients with limited choices in treating refractory angina, according to a recent randomized trial. Despite not increasing perfusion as expected, the device significantly reduced symptoms and had a low rate of complications.
Source: Medscape - 🏆 386. / 55 Read more »
Comparing Bispecific Antibodies and CAR T-Cell Therapy for Relapsed/Refractory ALLThe benefits and limitations of bispecific antibodies and CAR T-cell therapy for relapsed/refractory acute lymphoblastic leukemia (ALL) were discussed at a recent conference. Experts suggest that bispecific antibodies should be used before CAR T-cell therapy.
Source: Medscape - 🏆 386. / 55 Read more »
20kg of ketamine seized from international traveler at O'HareAn international traveler was accused of trying to smuggle 20 kilograms of ketamine in his luggage last weekend at O'Hare Airport.
Source: fox32news - 🏆 547. / 51 Read more »
Pilot in Ariz. hot air balloon crash given ketamine by first responders, contrary to original reportThe pilot of a hot air balloon that crashed in Arizona in January, killing him and three passengers did not have ketamine in his body when the balloon fell, contrary to initial reports from officials earlier this week.
Source: WashTimes - 🏆 235. / 63 Read more »